Pneumonia Testing Market Research Report Information By Product Type (Consumable and Analyzer), By Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluroscence, Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), and Others), By Method Type (Immunodiagnostic, Molecular Diagnostic, and Point-of-Care (POC) Testing), By End-user (Hospitals, Diagnostic Centers, and Others), By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Pneumonia Testing Market Overview

The Pneumonia Testing Market Size was valued at USD 0.7 Billion in 2022. The pneumonia testing market industry is projected to grow from USD 0.74 Billion in 2023 to USD 1.017 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.00% during the forecast period (2024 - 2032). The use of point-of-care (POC) testing and advancements in nucleic acid detection technology are the primary market drivers of the pneumonia testing market growth. Furthermore, the market is growing due to the growing elderly population, the rapid advancements in pneumonia diagnostics, and the rising prevalence of pneumonia in children.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Pneumonia Testing Market Trends

• Concerns about pneumonia mortality and increased pneumonia prevalence are driving the market growth

One of the main factors anticipated to drive the growth of the market CAGR is the notable increase in the prevalence of pneumonia worldwide. Pneumonia is generally more common in the elderly and pediatric populations. For instance, according to a 2019 United Nations International Children's Emergency Fund (UNICEF) article, there are more than 1,400 instances of pneumonia worldwide for every 100,000 people. Additionally, with 2,500 instances and 1,620 cases per 100,000 children, respectively, South Asia and West and Central Africa had the highest incidences of it. As a result, the aforementioned variables are significant market growth drivers. Among all infectious diseases, pneumonia is regarded as one of the most frequent causes of hospitalization. If the patient is determined to be critically ill, additional microbiological testing for pneumonia is performed while the patient is hospitalized. For instance, according to estimates from the American Thoracic Society (ATS), each year, approximately 1.0 million adult Americans seek hospital care as a result of pneumonia. Guidelines for Community-Acquired Pneumonia (CAP) were released by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) since developed countries are also increasingly concerned about pneumonia testing. It is anticipated that developing countries will follow these standards for pneumonia testing in order to raise awareness of the testing protocols. Therefore, the variables listed above are important catalysts for the expansion of the  market throughout the anticipated period.

Pneumonia testing market developments over time have included a change in consumer preferences and a rise in the demand for point-of-care diagnostics. Rapid diagnostic tools are desperately needed since pneumonia is becoming more common. The point-of-care testing segment is becoming popular among patients and healthcare professionals due to its main advantages, which include convenience, faster diagnosis times, and better treatment outcomes. As per a January 2020 NCBI post, quick syndromic molecular testing for pneumonia provide more accurate diagnosis than the present gold standard of culture. The study indicated that commercially available syndromic diagnostic testing platforms, such as Unyvero and Filmarray Pneumonia panel, are more effective at detecting pneumonia than a traditional diagnostic technique.

The pneumonia testing market is growing thanks to the development of new, more precise, sensitive, and targeted testing techniques. Point-of-care (POC) testing is being used more often to identify pneumonia due to its increased efficacy and quick turnaround time for test results. The more sophisticated multiplex PCR (mPCR)-based pneumonia testing technology offers improved detection efficiency at a lower cost and in less time. Additionally, the use of antibiotics in the past had no effect on the DNA or RNA replication of minuscule microbes because it does not require live microorganisms. Point-of-care testing is, therefore, being driven by the increased prevalence of chronic diseases among a broad consumer base that is adopting quick, affordable diagnostic testing. The POC test's ability to provide quick and precise results contributes to the advancement of patient-centered healthcare in bedside settings, which in turn encourages the use of point-of-care testing and, ultimately, the expansion of the pneumonia testing market. Thus, driving the pneumonia testing market revenue.

Pneumonia Testing Market Segment Insights

Pneumonia Testing Product Type Insights

The Pneumonia Testing market segmentation, based on product type includes Consumable and Analyzer. The analyzer segment dominated the market, which was attributed to rises in pneumonia cases worldwide, development in technology, and increased need for accurate and prompt diagnostic services. Due to their ability to deliver rapid turnaround times and improve diagnostic accuracy through automated and effective testing procedures, analyzers are becoming more and more popular in the market.

Pneumonia Testing Technology Insights

The Pneumonia Testing market segmentation, based on technology, includes Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluroscence, Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), and Others. The enzyme-linked immunosorbent assay (ELISA) category generated the most income. The demand for ELISA is expected to be driven throughout the forecast period by the prevalence of infectious diseases such as dengue, hepatitis, AIDS, neurological disorders, and cancer. In addition, it finds utility in a wide range of other fields, including toxicology, immunology, drug development, transplantation, pharmaceuticals, infectious diseases, cancer, and protein measurement.

Figure 1:  Pneumonia Testing Market, by Technology, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Pneumonia Testing Method Type Insights

The Pneumonia Testing market segmentation, based on method type, includes Immunodiagnostic, Molecular Diagnostic, and Point-of-Care (POC) Testing. The point-of-care (POC) testing category generated the most income. POC testing is a cutting-edge method that is currently the best way to identify pneumonia. POC testing is becoming more widely used, which can be ascribed to its higher efficiency, an increase in pneumonia cases, and its highly preferred rapid test results.

Pneumonia Testing End User Insights

The Pneumonia Testing market segmentation, based on end user, includes Hospitals, Diagnostic Centers, and Others. The hospitals category generated the most income. The growth can be linked to several pneumonia-related hospital admissions. In addition, advantageous reimbursement policies, increased public awareness, and the need for pneumonia testing are important factors driving the rise of the hospitals segment.

Pneumonia Testing Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Pneumonia Testing market area will dominate this market. The increasing rate of pneumonia cases in the area served as a market driver for the market's expansion. The market is also growing as a consequence of the presence of major players in the field and the ongoing advancement of advanced PCR-based technologies that provide faster test results.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2:  PNEUMONIA TESTING MARKET SHARE BY REGION 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Pneumonia Testing market accounts for the second-largest market share. During the forecast period, demand for pneumonia diagnostics products in Europe is expected to expand at a robust rate due to the rising prevalence of chronic diseases and an aging population. Similarly, during the next ten years, the pneumonia diagnostics market will likely benefit from the growing medical tourism industry as well as technological developments in diagnostics. Further, the German Pneumonia Testing market held the largest market share, and the UK Pneumonia Testing market was the fastest growing market in the European region.

The Asia-Pacific Pneumonia Testing Market is expected to grow at the fastest CAGR from 2024 to 2032. Since the elderly population is more prone to pneumonia, the growing geriatric population in Asia Pacific is significantly increasing the prevalence of pneumonia. Additionally, hospitalization rates are higher among the elderly, which has a substantial effect on morbidity and death. Moreover, China’s Pneumonia Testing market held the largest market share, and the Indian Pneumonia Testing market was the fastest growing market in the Asia-Pacific region.

Pneumonia Testing Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Pneumonia Testing market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Pneumonia Testing industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Pneumonia Testing industry to benefit clients and increase the market sector. In recent years, the Pneumonia Testing industry has offered some of the most significant advantages to medicine. Major players in the Pneumonia Testing market are attempting to increase market demand by investing in research and development operations, including Bio-Rad Laboratories, Inc., Abbott, BioMérieux SA, Meridian Bioscience, Hologic Inc., Becton, Dickinson and Company, Curetis, Thermo Fisher Scientific, and Quidel Corporation.

Hologic Inc. is a company that develops, produces, and distributes surgical supplies, diagnostic tools, and medical imaging equipment. Along with GYN surgical products like hysteroscopic tissue removal systems and endometrial ablation systems, it also provides skeletal health products like dual-energy X-ray bone densitometry systems and mini C-arm imaging, as well as products that support human disease diagnosis and accessories and products related to breast imaging. The company supplies its goods to a variety of clientele, including hospitals, clinics, surgeons, and other medical professionals.

Development, production, and distribution of diagnostic test kits for viral, gastrointestinal, respiratory, and parasitic infectious disease indications are all done by the fully integrated life science company Meridian Bioscience Inc. (Meridian). In addition, the business produces bulk antigens, antibodies, nucleotides, purified reagents, and associated goods for use in manufacturing diagnostics and conducting research. It creates proteins and other biological materials for use in medicines and vaccine development biotechnology research.

Key companies in the pneumonia testing market include

• Bio-Rad Laboratories, Inc.


• Abbott


• BioMérieux SA


• Meridian Bioscience


• Hologic Inc.


• Becton, Dickinson and Company


• Curetis


• Thermo Fisher Scientific


• Quidel Corporation

Pneumonia Testing Industry Developments

May 2022: The novel LIAISON B•R•A•H•M•S MR-proADM immunodiagnostic test is being developed and commercialized by B•R•A•H•M•S GmbH, a partner of Thermo Fisher Scientific, in collaboration with DiaSorin S.p.A. Infections of the lower respiratory tract, urinary tract, renal illness, sepsis, and septic shock can all be diagnosed with the help of this assay.

September 2021: With the purpose of identifying the primary pathogens linked to atypical pneumoniae, CerTest Biotec created and verified the CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae, & L. pneumophila real-time PCR kit.

Pneumonia Testing Market Segmentation

Pneumonia Testing Product Type Outlook

• Consumable


• Analyzer

Pneumonia Testing Technology Outlook

• Enzyme-Linked Immunosorbent Assay (ELISA)


• Immunofluroscence


• Immunohistochemistry (IHC)


• Polymerase Chain Reaction (PCR)


• Others

Pneumonia Testing Method Type Outlook

• Immunodiagnostic


• Molecular Diagnostic


• Point-of-Care (POC) Testing

Pneumonia Testing End User Outlook

• Hospitals


• Diagnostic Centers


• Others

Pneumonia Testing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America